summary：
[Generated Title]: Hims & Hers: Profitable Now, But Will It Survive the Hype?So, Hims & H... [Generated Title]: Hims & Hers: Profitable Now, But Will It Survive the Hype?
So, Hims & Hers (HIMS). Another one of these "disruptive" companies that promises to revolutionize healthcare with…online subscriptions? Give me a break.
The Numbers Game: Smoke and Mirrors?
Let's look at the Q3 numbers. Revenue's up nearly 50% year-over-year, subscribers are up 21%. Net income is positive. Cool. Adjusted EBITDA is also up. All sounds great on paper, right?
But here's what gets me. "Adjusted" EBITDA. What exactly are they "adjusting" out? Stock-based compensation? Acquisition costs? Conveniently leaving out all the messy bits that make the picture less rosy. Every damn company does this now. It's like they think we're idiots.
And the gross margin dropped from 79% to 74%. That's not exactly going in the right direction, is it? Sure, they're still making a killing, but the trendline matters. Are they cutting corners? Are competitors nipping at their heels? Are they getting ready to squeeze the consumer even harder?
They're talking about discussions with Novo Nordisk for Wegovy distribution. That's interesting. Another potential revenue stream tied to the latest weight loss craze. But is it sustainable? Is this the future of healthcare, or just chasing trends? How many people are going to stick with these subscriptions after they lose the weight?
The Roller Coaster Ride: Investor Sentiment
The article mentions HIMS stock has been a "roller coaster ride" this year. Up 173%, then down 63%. Up again, then another plunge. Sounds about right for a meme stock. HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
And get this – analysts are all over the place. Some say "hold," others say "reduce." The average price target is $45.27, which is a potential upside of 24.51%. Okay, maybe. But then you see short interest is a whopping 37.54% of the float. That's a lot of people betting against this thing. Who are we supposed to believe?
Then again, maybe I'm the crazy one here. Maybe this is the future of healthcare. Personalized, convenient, direct-to-consumer. But let's be real.
They also offer compounded GLP-1 injections, same ingredients as Ozempic and Wegovy. So, generic weight loss drugs? How is that innovative? Sounds like they are just riding the wave of a trend, hoping the hims stock price goes up.
Oh, and institutional ownership is strong at 64%. "Smart money's bullish stance," they say. Right. The same "smart money" that loaded up on WeWork? Please.
The "Vision": What Are They Really Selling?
The CEO, Andrew Dudum, says they're "building a platform that gets more personal, more proactive, and resonates with more people as we scale." What does that even mean? It's corporate buzzword bingo. "Personalized care, from the comfort of their own home." Translation: We'll send you pills in the mail after a five-minute online consultation.
And their "mission to help the world feel great through the power of better health"? It's so disgustingly generic. It's like they pulled it out of a fortune cookie.
I also find it interesting that they are saying that they are trying to make significant progress in establishing hims and hers as a truly global brand. I wonder how that will work, considering healthcare regulations around the world.
So, Are We Buying Snake Oil?
Hims & Hers might be profitable now, but I still don't trust it. It feels like a house of cards built on hype and investor speculation. So many things could go wrong. Competition, regulation, changing consumer tastes. The whole damn thing could collapse. And honestly, I wouldn't be surprised.